Gloria Biosciences

Gloria Biosciences () is a commercial stage biopharma company founded in 2016, bringing together a seasoned development and management team with global versions, and dedications to developing patient-centered treatments. In 2021, Gloria Bio has successfully launched and commercialized a novel, fully human anti-PD-1 mAb, zimberelimab ("Yutuo","”), for the treatment of relapsed or refractory classical Hodgkin’s lymphoma, which demonstrated an overall response rate (ORR) of 92.86%, DCR of 96.43%, and 12 month overall survival rate of 99% with improved long-term survival benefits for patients. Zimberelimab is also designated as Breakthrough Therapy by China's Center for Drug Evaluation for the treatment of recurrent or metastatic cervical cancer, which has been approved in July 2023, marking the first and only PD-1 mAb approved in China for cervical cancer, and third globally. Currently, zimberelimab is being evaluated in multiple types of cancer, including prostate, colorectal, non-small cell lung, pancreatic, triple-negative breast, head and neck, and renal cell cancers, etc. It is also being studied in combinations with multiple innovative drugs, targeting CD47, CD73, TIGIT, A2aR, CCR8, LAG-3, CD40, CD39, Trop-2, CAR-T, HER-2 ACD and Neo-T, etc. Gloria Biosciences is striving to build a pipeline with more effective treatment alternative for cancer patients, including LAG-3 and other innovative monoclonal and biospecific antibodies.